Study on the Effect of 24 Months of Teriparatide Therapy on Bone Microarchitecture and Bone Volume in Postmenopausal Women With Osteoporosis

Trial Profile

Study on the Effect of 24 Months of Teriparatide Therapy on Bone Microarchitecture and Bone Volume in Postmenopausal Women With Osteoporosis

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 May 2017

At a glance

  • Drugs Teriparatide (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 02 May 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2021.
    • 02 May 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2020.
    • 12 Jul 2013 Planned end date changed from 1 Jan 2014 to 1 Jan 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top